Where can I buy shares of SLS?
Shares of SLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
What is happening with the Sellas Life Sciences Group stock price?
The SELLAS Life Sciences Group Inc. stock price fell by -4.72% on the last day (Monday, 14th Feb 2022) from $6.15 to $5.86. and has now fallen 3 days in a row. During the day the stock fluctuated 7.02% from a day low at $5.84 to a day high of $6.25.
Why is the share price down 88%?
The share price decline has continued throughout the most recent three months, down 88%, suggesting an absence of enthusiasm from investors. Basically, most investors should be wary of buying into a poor-performing stock, unless the business itself has clearly improved.
Why did oil prices crash to five-week lows ahead of Fed meeting?
Oil prices plunged to five-week lows on Tuesday ahead of the Federal Reserve's meeting where it was expected to announce a large interest rate hike to tame inflation that hit 40-year highs in May.
Is SLS stock a buy right now?
3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for SELLAS Life Sciences Group in the last year. There are currently...
Will SELLAS Life Sciences Group's stock price go up in 2022?
3 Wall Street research analysts have issued 1-year price targets for SELLAS Life Sciences Group's shares. Their forecasts range from $14.00 to $21....
How has SELLAS Life Sciences Group's stock price performed in 2022?
SELLAS Life Sciences Group's stock was trading at $5.53 on January 1st, 2022. Since then, SLS shares have decreased by 46.3% and is now trading at...
When is SELLAS Life Sciences Group's next earnings date?
SELLAS Life Sciences Group is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forec...
How were SELLAS Life Sciences Group's earnings last quarter?
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) issued its earnings results on Thursday, May, 12th. The company reported ($1.05) earnings per share (...
When did SELLAS Life Sciences Group's stock split? How did SELLAS Life Sciences Group's stock split work?
SELLAS Life Sciences Group's stock reverse split on Friday, November 8th 2019. The 1-50 reverse split was announced on Wednesday, November 6th 2019...
Who are SELLAS Life Sciences Group's key executives?
SELLAS Life Sciences Group's management team includes the following people: Dr. Angelos M. Stergiou M.D. , ScD h.c., Founder, Pres, CEO & Directo...
Who are some of SELLAS Life Sciences Group's key competitors?
Some companies that are related to SELLAS Life Sciences Group include Prelude Therapeutics (PRLD) , Nature's Sunshine Products (NATR) , Rallybio...
What is SELLAS Life Sciences Group's stock symbol?
SELLAS Life Sciences Group trades on the NASDAQ under the ticker symbol "SLS."
What is the price target for SLS in 2021?
On Jul 21, 2021 "Cantor Fitzgerald" gave "$18.00" rating for SLS. The price target was changed from $8.60 to 0.5% .
Is SELLAS Life Sciences Group Inc. stock A Buy?
SELLAS Life Sciences Group Inc. holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Hold/Accumulate to a Sell candidate.
What is the SLS symbol?
SELLAS Life Sciences Group trades on the NASDAQ under the ticker symbol "SLS."
When did SELLAS Life Sciences Group's stock split? How did SELLAS Life Sciences Group's stock split work?
Shares of SELLAS Life Sciences Group reverse split on the morning of Friday, November 8th 2019. The 1-50 reverse split was announced on Wednesday, November 6th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 7th 2019. An investor that had 100 shares of SELLAS Life Sciences Group stock prior to the reverse split would have 2 shares after the split.
What is SELLAS Life Sciences Group's stock symbol?
SELLAS Life Sciences Group trades on the NASDAQ under the ticker symbol "SLS."
How much money does SELLAS Life Sciences Group make?
SELLAS Life Sciences Group has a market capitalization of $93.25 million and generates $1.90 million in revenue each year. The company earns $-16.76 million in net income (profit) each year or ($1.19) on an earnings per share basis.
Where are SELLAS Life Sciences Group's headquarters?
SELLAS Life Sciences Group is headquartered at 15 WEST 38TH STREET 10TH FLOOR, NEW YORK NY, 10018.
What is SELLAS Life Sciences?
SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company. It engages in the development and commercialization of immunotherapeutic for cancer indications. The firm's product pipeline includes galinpepimut-S and nelipepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.
When is the 1-50 reverse split?
The 1-50 reverse split was announced on Wednesday, November 6th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 7th 2019. An investor that had 100 shares of SELLAS Life Sciences Group stock prior to the reverse split would have 2 shares after the split.
Why was the $Kura trial sidelined?
The FDA sidelined an early-stage cancer trial from $Kura Oncology after a patient died due to a serious adverse event related to the oral treatment's mechanism of action.
What is the cause of death in Kura Oncology?
The cause of death in Kura Oncology's early-stage cancer trial, differentiation syndrome, is seen in some treatments for acute myeloid leukemia (AML) and was included in the black box warning of an AML drug approved by the FDA in 2018. (FDA)
Why did the 3D Medicines license increase?
The increase was primarily due to amortization expense associated with the capitalized contract acquisition costs of the 3D Medicines license agreement as well as an increase in legal fees as compared to the same period in 2020 during which the majority of legal expenses were offset by a reimbursement credit.
